Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access

The DELIVER study

Jawed Polad, Jochen Wöhrle, Balbir Singh, Milan Chag, Seung-Woon Rha, Fazila Tun Nesa Malik, Martijn van Eck, Wolfgang Rottbauer

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background/Purpose: DELIVER (DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER stenting) was a prospective, multicenter, all-comers registry to assess the deliverability of the Resolute Integrity™ zotarolimus-eluting stent (R-ZES). Methods/Materials: Patients (n = 7740 patients, 10449 lesions) undergoing percutaneous coronary intervention and deemed suitable for R-ZES implantation were enrolled and treated according to standard practice of the participating centers in 30 countries. Outcomes included delivery success and in-hospital target lesion failure (TLF), major adverse cardiac event (MACE), and Academic Research Consortium definite/probable stent thrombosis. We performed a post hoc analysis comparing deliverability, in-hospital clinical outcomes and resource utilization with radial vs. femoral access. Results: A high proportion of the population had complex disease (71%): mean lesion length was 26.7 ± 17.5. mm, 35% of lesions were moderately/severely calcified and 17% were bifurcated. Femoral and radial accesses were used in 53% and 46% of patients, respectively. Patients treated using femoral access had more complex coronary artery disease. Primary delivery success was 98.9% and did not differ by approach. Radial access was associated with lower stent and balloon utilization, but higher guide catheter utilization, lower procedure duration, and contrast administered compared with femoral access. In-hospital TLF and MACE occurred in 1.6% of patients; definite or probable stent thrombosis occurred in 0.2%. Clinical outcomes did not differ by vascular access. Conclusions: R-ZES was found to be highly deliverable in a complex, all-comers, international population, regardless of whether radial or femoral access was used. In-hospital outcomes were excellent with very low risk of complications.

Original languageEnglish
Pages (from-to)289-294
Number of pages6
JournalCardiovascular Revascularization Medicine
Volume15
Issue number5
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Thigh
Stents
Thrombosis
Percutaneous Coronary Intervention
Population
Blood Vessels
Registries
Coronary Artery Disease
Catheters
Research
zotarolimus

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access : The DELIVER study. / Polad, Jawed; Wöhrle, Jochen; Singh, Balbir; Chag, Milan; Rha, Seung-Woon; Malik, Fazila Tun Nesa; van Eck, Martijn; Rottbauer, Wolfgang.

In: Cardiovascular Revascularization Medicine, Vol. 15, No. 5, 01.01.2014, p. 289-294.

Research output: Contribution to journalArticle

Polad, Jawed ; Wöhrle, Jochen ; Singh, Balbir ; Chag, Milan ; Rha, Seung-Woon ; Malik, Fazila Tun Nesa ; van Eck, Martijn ; Rottbauer, Wolfgang. / Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access : The DELIVER study. In: Cardiovascular Revascularization Medicine. 2014 ; Vol. 15, No. 5. pp. 289-294.
@article{3625fd21859e47dd988b1da3c9e26053,
title = "Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access: The DELIVER study",
abstract = "Background/Purpose: DELIVER (DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER stenting) was a prospective, multicenter, all-comers registry to assess the deliverability of the Resolute Integrity™ zotarolimus-eluting stent (R-ZES). Methods/Materials: Patients (n = 7740 patients, 10449 lesions) undergoing percutaneous coronary intervention and deemed suitable for R-ZES implantation were enrolled and treated according to standard practice of the participating centers in 30 countries. Outcomes included delivery success and in-hospital target lesion failure (TLF), major adverse cardiac event (MACE), and Academic Research Consortium definite/probable stent thrombosis. We performed a post hoc analysis comparing deliverability, in-hospital clinical outcomes and resource utilization with radial vs. femoral access. Results: A high proportion of the population had complex disease (71{\%}): mean lesion length was 26.7 ± 17.5. mm, 35{\%} of lesions were moderately/severely calcified and 17{\%} were bifurcated. Femoral and radial accesses were used in 53{\%} and 46{\%} of patients, respectively. Patients treated using femoral access had more complex coronary artery disease. Primary delivery success was 98.9{\%} and did not differ by approach. Radial access was associated with lower stent and balloon utilization, but higher guide catheter utilization, lower procedure duration, and contrast administered compared with femoral access. In-hospital TLF and MACE occurred in 1.6{\%} of patients; definite or probable stent thrombosis occurred in 0.2{\%}. Clinical outcomes did not differ by vascular access. Conclusions: R-ZES was found to be highly deliverable in a complex, all-comers, international population, regardless of whether radial or femoral access was used. In-hospital outcomes were excellent with very low risk of complications.",
keywords = "Deliverability, Radial access, Resolute integrity, Zotarolimus-eluting stent",
author = "Jawed Polad and Jochen W{\"o}hrle and Balbir Singh and Milan Chag and Seung-Woon Rha and Malik, {Fazila Tun Nesa} and {van Eck}, Martijn and Wolfgang Rottbauer",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.carrev.2014.07.002",
language = "English",
volume = "15",
pages = "289--294",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Deliverability of the Resolute Integrity stent and a post hoc comparison of radial and femoral access

T2 - The DELIVER study

AU - Polad, Jawed

AU - Wöhrle, Jochen

AU - Singh, Balbir

AU - Chag, Milan

AU - Rha, Seung-Woon

AU - Malik, Fazila Tun Nesa

AU - van Eck, Martijn

AU - Rottbauer, Wolfgang

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background/Purpose: DELIVER (DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER stenting) was a prospective, multicenter, all-comers registry to assess the deliverability of the Resolute Integrity™ zotarolimus-eluting stent (R-ZES). Methods/Materials: Patients (n = 7740 patients, 10449 lesions) undergoing percutaneous coronary intervention and deemed suitable for R-ZES implantation were enrolled and treated according to standard practice of the participating centers in 30 countries. Outcomes included delivery success and in-hospital target lesion failure (TLF), major adverse cardiac event (MACE), and Academic Research Consortium definite/probable stent thrombosis. We performed a post hoc analysis comparing deliverability, in-hospital clinical outcomes and resource utilization with radial vs. femoral access. Results: A high proportion of the population had complex disease (71%): mean lesion length was 26.7 ± 17.5. mm, 35% of lesions were moderately/severely calcified and 17% were bifurcated. Femoral and radial accesses were used in 53% and 46% of patients, respectively. Patients treated using femoral access had more complex coronary artery disease. Primary delivery success was 98.9% and did not differ by approach. Radial access was associated with lower stent and balloon utilization, but higher guide catheter utilization, lower procedure duration, and contrast administered compared with femoral access. In-hospital TLF and MACE occurred in 1.6% of patients; definite or probable stent thrombosis occurred in 0.2%. Clinical outcomes did not differ by vascular access. Conclusions: R-ZES was found to be highly deliverable in a complex, all-comers, international population, regardless of whether radial or femoral access was used. In-hospital outcomes were excellent with very low risk of complications.

AB - Background/Purpose: DELIVER (DELiverability of the Resolute Integrity Stent in All-Comer Vessels and Cross-OvER stenting) was a prospective, multicenter, all-comers registry to assess the deliverability of the Resolute Integrity™ zotarolimus-eluting stent (R-ZES). Methods/Materials: Patients (n = 7740 patients, 10449 lesions) undergoing percutaneous coronary intervention and deemed suitable for R-ZES implantation were enrolled and treated according to standard practice of the participating centers in 30 countries. Outcomes included delivery success and in-hospital target lesion failure (TLF), major adverse cardiac event (MACE), and Academic Research Consortium definite/probable stent thrombosis. We performed a post hoc analysis comparing deliverability, in-hospital clinical outcomes and resource utilization with radial vs. femoral access. Results: A high proportion of the population had complex disease (71%): mean lesion length was 26.7 ± 17.5. mm, 35% of lesions were moderately/severely calcified and 17% were bifurcated. Femoral and radial accesses were used in 53% and 46% of patients, respectively. Patients treated using femoral access had more complex coronary artery disease. Primary delivery success was 98.9% and did not differ by approach. Radial access was associated with lower stent and balloon utilization, but higher guide catheter utilization, lower procedure duration, and contrast administered compared with femoral access. In-hospital TLF and MACE occurred in 1.6% of patients; definite or probable stent thrombosis occurred in 0.2%. Clinical outcomes did not differ by vascular access. Conclusions: R-ZES was found to be highly deliverable in a complex, all-comers, international population, regardless of whether radial or femoral access was used. In-hospital outcomes were excellent with very low risk of complications.

KW - Deliverability

KW - Radial access

KW - Resolute integrity

KW - Zotarolimus-eluting stent

UR - http://www.scopus.com/inward/record.url?scp=84907308460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907308460&partnerID=8YFLogxK

U2 - 10.1016/j.carrev.2014.07.002

DO - 10.1016/j.carrev.2014.07.002

M3 - Article

VL - 15

SP - 289

EP - 294

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 5

ER -